$4.69 -0.15 (-3.10%)
2/10/2012 3:59 PM

DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA)

CAPS Rating: 3 out of 5

A dermatology company, which is engaged in the development and marketing Levulan photodynamic therapy and other products for common skin conditions.

Results 1 - 3 of 3

Recs

0
Member Avatar cbibuld (30.26) Submitted: 1/12/2012 4:48:48 PM : Outperform Start Price: $4.60 DUSA Score: -2.49

Company earnings turned positive 2nd hald of 2011 and look to be continuing down that path. Last year grew +20% revenues. Thompson puts street est of .13/.12 for 4th qtr. Y/y would equal .30/.11 p/s.

Report this Post Add Comment | Reply | Permalink

Recs

1
Member Avatar Turtlebale (40.24) Submitted: 3/3/2011 1:27:32 PM : Outperform Start Price: $4.18 DUSA Score: +11.31

great growth, low valuation

Report this Post Add Comment | Reply | Permalink

Recs

1
Member Avatar cibient (89.47) Submitted: 10/26/2010 10:53:35 AM : Outperform Start Price: $2.45 DUSA Score: +78.20

Pharm micro-cap with a good balance sheet and real revenues with a few established products (primary one is Levulan Kerastick).

http://seekingalpha.com/article/222372-dusa-a-great-value-in-micro-cap-biotech

Report this Post 1 Comment | Reply | Permalink
Results 1 - 3 of 3

Featured Broker Partners


Advertisement